Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.70 |
| ▸ | RELA | Q04206 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NMT1 | P30419 | 1/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10716420 | 0.85 | TGM2 (0.59) | NPC1RAB9ASMN1; SMN2TSHRNFKB1 | |
| SCHEMBL23918242 | 0.85 | DDAH1 (0.64) | NPC1RAB9ASMN1; SMN2TSHRNFKB1 | |
| SCHEMBL10716411 | 0.85 | TGM2 (0.59) | NPC1RAB9ASMN1; SMN2TSHRNFKB1 | |
| SCHEMBL10716405 | 0.85 | TGM2 (0.59) | NPC1RAB9ASMN1; SMN2TSHRNFKB1 | |
| SCHEMBL20284039 | 0.84 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2TSHRNFKB1 | |
| SCHEMBL17675351 | 0.82 | SMN1; SMN2 (0.68) | NPC1RAB9ASMN1; SMN2TSHRNFKB1 | |
| SCHEMBL11759969 | 0.82 | SMN1; SMN2 (0.68) | NPC1RAB9ASMN1; SMN2TSHRNFKB1 | |
| SCHEMBL2998577 | 0.82 | SMN1; SMN2 (1.00) | NPC1RAB9ASMN1; SMN2TSHRNFKB1 | |
| SCHEMBL4135335 | 0.82 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2TSHRNFKB1 | |
| SCHEMBL5645657 | 0.82 | SMN1; SMN2 (0.68) | NPC1RAB9ASMN1; SMN2TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833203-B2 | Synthetic retinoids (in cell modulation) | UNIVERSITY OF DURHAM | 2023-12-05 | — | — | US | disclosed |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-10-03 | — | — | US | disclosed |
| US-11324825-B2 | Synthetic retinoids (in cell modulation) | UNIVERSITY OF DURHAM | 2022-05-10 | — | — | US | disclosed |
| US-20190209684-A1 | Synthetic Retinoids (in Cell Modulation) | UNIVERSITY OF DURHAM (GB) | 2019-07-11 | — | — | US | disclosed |
| US-20190209685-A1 | SYNTHETIC RETINOIDS (IN CELL MODULATION) | UNIVERSITY OF DURHAM (GB) | 2019-07-11 | — | — | US | disclosed |
| WO-2018029473-A1 | SYNTHETIC RETINOIDS (IN CELL MODULATION) | UNIVERSITY OF DURHAM (GB) | 2018-02-15 | — | — | WO | disclosed |
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| WO-2010129467-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF RENIN, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129467-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF RENIN, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-2243779-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
| EP-1905762-A1 | PYRAZOLONE DERIVATIVE | Genecare Research Institute Co., Ltd (JP) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833203-B2 | Synthetic retinoids (in cell modulation) | RARA, RARB, RXRA | NPC1 1449/4885RAB9A 848/4885SMN1; SMN2 2432/4885 |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, DEGS1, SMPD1 | NPC1 59/4885RAB9A 952/4885SMN1; SMN2 588/4885 |
| US-11324825-B2 | Synthetic retinoids (in cell modulation) | RARA, RARB, RXRA | NPC1 1449/4885RAB9A 848/4885SMN1; SMN2 2432/4885 |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | NPC1 2018/4885RAB9A 418/4885SMN1; SMN2 4394/4885 |
| US-20190209685-A1 | SYNTHETIC RETINOIDS (IN CELL MODULATION) | RARA, RARB, RXRA | NPC1 1449/4885RAB9A 848/4885SMN1; SMN2 2432/4885 |
| US-20190209684-A1 | Synthetic Retinoids (in Cell Modulation) | RARA, RARB, RXRA | NPC1 1449/4885RAB9A 848/4885SMN1; SMN2 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.